Lv31
206 积分 2024-08-07 加入
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
1小时前
待确认
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
2小时前
已完结
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
15天前
已完结
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
16天前
已完结
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
16天前
已完结
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
16天前
已完结
Homing in on a Moving Target: Androgen Receptor Cistromic Plasticity in Prostate Cancer
2个月前
已完结
The breast cancer drug market
3个月前
已完结
Differences in Breast Cancer Stage at Diagnosis and Cancer-Specific Survival by Race and Ethnicity in the United States
3个月前
已完结
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies
3个月前
已完结
皖公网安备34019202002308
